Drug Profile


Alternative Names: BAY-57-9352; Telatinib mesylate

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Bayer
  • Developer ACT Biotech; Eddingpharm
  • Class Antineoplastics; Furans; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • No development reported Colorectal cancer

Most Recent Events

  • 04 Aug 2015 No recent reports on development identified - Phase-I for Colorectal cancer in USA (PO)
  • 08 Jan 2014 Telatinib licensed to Eddingpharm worldwide
  • 31 Jan 2012 ACT Biotech completes a phase II trial in Gastric cancer (First-line therapy, Late-stage disease, Combination therapy) in USA and Spain (NCT00952497)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top